Leukemia Mieloid Kronis (CML)

01Pathophysiology

CML originates from a reciprocal translocation between chromosomes 9 and 22, written as t(9;22)(q34;q11.2). This event fuses the ABL1 proto-oncogene on chromosome 9 with the BCR (breakpoint cluster region) gene on chromosome 22. The result is a shortened chromosome 22, known as the Philadelphia chromosome, which encodes the BCR-ABL1 fusion protein.

The BCR-ABL1 protein is a constitutively active tyrosine kinase. Under normal conditions, ABL1 kinase activity is tightly regulated and participates in cell signaling related to growth and differentiation. Once fused with BCR, the kinase becomes permanently "switched on," driving several downstream pathways including RAS/MAPK, JAK/STAT, and PI3K/AKT. The net effect is uncontrolled proliferation of myeloid progenitor cells, resistance to apoptosis, and altered adhesion of leukemic cells to the bone marrow stroma, which allows premature release of immature cells into the peripheral blood.

This explains why the peripheral smear in CML shows an orderly left shift: you see the entire spectrum of granulocyte maturation, from blasts and promyelocytes through to fully mature neutrophils, rather than a "maturation arrest" as seen in acute leukemias. The bone marrow is hypercellular and packed with granulocytic precursors, which crowds out normal hematopoiesis over time and causes the marrow to expand, contributing to the marked splenomegaly through extramedullary hematopoiesis.

Basophilia is a hallmark because the neoplastic clone differentiates along all granulocyte lineages, and basophils are particularly prominent. An increasing basophil count can signal disease progression. The low LAP score distinguishes CML from a leukemoid reaction: in reactive leukocytosis, mature neutrophils are enzymatically active (high LAP), whereas in CML, the neutrophils are clonal and functionally abnormal (low LAP).

02Classification and Clinical Manifestation

CML progresses through three recognized phases. The clinical behavior, prognosis, and treatment strategy differ substantially across these phases.

Additional clinical features worth noting across phases:

03Diagnostic Workup

Best Initial Test: The evaluation starts with a CBC with differential and peripheral smear. The classic picture is striking leukocytosis with an orderly left shift and basophilia. This combination in a middle-aged adult with splenomegaly should immediately raise suspicion for CML.

Most Accurate/Confirmatory Test: The diagnosis is confirmed by demonstrating the Philadelphia chromosome through bone marrow cytogenetics or, equivalently, by detecting the BCR-ABL1 fusion gene via FISH or RT-PCR on peripheral blood. In practice, RT-PCR is the most sensitive method and also serves as the baseline for monitoring treatment response. Conventional karyotyping on bone marrow is still recommended at diagnosis because it can reveal additional chromosomal abnormalities (clonal evolution) that carry prognostic significance.

The LAP score is a classic exam question discriminator. When a vignette describes a patient with very high WBC counts and you must distinguish between CML and a leukemoid reaction (e.g., from a severe infection), the LAP score is the differentiating test: low in CML, high in reactive processes.

After diagnosis, monitoring on TKI therapy relies on quantitative RT-PCR (measured as BCR-ABL1 transcript levels on the International Scale). Treatment milestones at 3, 6, and 12 months guide decisions about continuing, switching, or intensifying therapy.

04Management and Treatment

Acute Stabilization: When a patient presents with symptomatic leukocytosis or leukostasis (visual changes, priapism, respiratory distress), the immediate step is cytoreduction with hydroxyurea. Leukapheresis is added if symptoms are severe. These are temporizing measures while the definitive diagnosis is being established.

Long-term Management: Once CML is confirmed, the cornerstone of therapy is a tyrosine kinase inhibitor. Imatinib was the original breakthrough drug and remains a valid first-line option at 400 mg daily. It competitively inhibits the ATP-binding site of the BCR-ABL1 kinase, shutting down the proliferative signal. Second-generation TKIs (dasatinib, nilotinib, bosutinib) are more potent and are increasingly used upfront, particularly for patients with higher-risk disease scores.

Treatment is monitored with quantitative RT-PCR at defined milestones. A major molecular response (BCR-ABL1 <= 0.1% IS) by 12 months indicates the TKI is working. Failure to meet milestones triggers mutation analysis and consideration of switching therapy.

Contraindications and Side Effects to Know:

• Dasatinib carries a risk of pleural effusions and should be used cautiously in patients with pulmonary disease.

• Nilotinib can cause QT prolongation and pancreatitis; avoid in patients with significant cardiac history or pancreatitis risk.

• Ponatinib carries a risk of arterial thrombotic events (stroke, MI) and is reserved for T315I-mutated or multiply resistant disease.

• Imatinib side effects include periorbital edema, muscle cramps, nausea, and myelosuppression, but it has the longest safety track record.

Allogeneic hematopoietic stem cell transplant remains the only curative therapy but is reserved for patients who fail multiple TKIs, those with the T315I mutation (if ponatinib is not feasible), or those who progress to blast crisis. The transplant-related morbidity and mortality make it a second-line strategy in the TKI era.

In select patients who achieve sustained deep molecular response (BCR-ABL1 undetectable for >= 2 years), treatment-free remission (TKI discontinuation) can be attempted under close molecular monitoring, though roughly half will lose their response and need to restart therapy.

05Differential Diagnosis and Distractors

The single most important discriminator on the exam: the Philadelphia chromosome / BCR-ABL1 fusion is present in CML and absent in every other condition listed above. Among the myeloproliferative neoplasms, CML is the only one driven by BCR-ABL1, while the others are associated with JAK2, CALR, or MPL mutations.

06Traps and High-Yield Pearls

The most common way students miss CML questions is by confusing it with a leukemoid reaction. Both present with markedly elevated WBC counts and a left shift. The vignette trap is an older patient with very high WBC counts who also has some intercurrent infection, tempting you to attribute everything to a reactive process. The giveaway for CML is basophilia, a low LAP score, and splenomegaly out of proportion to any infection. If the vignette mentions any of these, you should suspect CML regardless of whether an infectious trigger is also described.

Another classic trap involves phase progression. A vignette may describe a known CML patient on imatinib who suddenly develops worsening fatigue, bleeding, and a blast count above 20%. Students sometimes treat this as a new AML diagnosis rather than recognizing it as blast crisis of CML, which changes the management approach entirely (combination of TKI plus induction chemotherapy, followed by transplant evaluation, rather than standard AML induction alone).

The T315I "gatekeeper" mutation is a frequently tested pearl. When a question stem describes a CML patient who fails multiple TKIs, the answer is ponatinib (or asciminib), because T315I confers resistance to imatinib, dasatinib, nilotinib, and bosutinib alike. Recognizing this mutation by name is often the key to selecting the correct drug.

Finally, do not confuse the Philadelphia chromosome in CML with its appearance in acute lymphoblastic leukemia (ALL). Philadelphia chromosome-positive ALL exists (particularly in adults), but the clinical presentation, blast phenotype, and treatment strategy are entirely different. If the vignette shows lymphoblasts with t(9;22), you are dealing with Ph+ ALL, not CML in blast crisis, unless there is a documented chronic phase history.

The core competency being tested in CML questions is the ability to connect a characteristic laboratory and physical exam pattern (leukocytosis with orderly maturation, basophilia, low LAP, splenomegaly) to the correct cytogenetic finding (Philadelphia chromosome), select the appropriate first-line therapy (TKI), and recognize when disease progression demands a change in strategy.